breast cancer cells

[Proceedings of the National Academy of Sciences of the United States of America] Employing the mouse mammary tumor virus]–PyMT mouse model of metastatic breast cancer, scientists compared the complete elimination of β-catenin with the specific ablation of its signaling outputs in mammary tumor cells.

[Acta Pharmacologica Sinica] Researchers showed that the expression of integrin α3 (ITGα3) and integrin β5 (ITGβ5) was upregulated in highly metastatic MDA-MB-231, MDA-MB-231BO breast cancer cell lines but was downregulated in poorly metastatic MCF-7 breast cancer cell line, which may have been the key targets of osthole’s anti-metastatic action.

[Scientific Reports] Scientists evaluated the phenotype switching associated with drug resistance in breast cancer cell lines and cell lineage obtained from Brazilian patients and highlighted the role of the cancer stem cell marker CD24 in the dynamics of cell plasticity and the acquirement of drug resistance.

[Communications Biology] Predicted pathogenic mutation R532Q within S5 disrupted the S5/S6 interaction leading to gain-of-function of the channel, which promoted breast cancer cell progression through strengthening of the TRPV6/PI3K interaction, activation of a PI3K/Akt/GSK-3β cascade, and up-regulation of epithelial-mesenchymal transition and anti-apoptosis.

[Molecular Oncology] Transcriptome analyses indicated that chronic estrogen receptor alpha (ERα) inhibition triggered a broad immunosuppressive program in ER-positive breast cancer cells, which was subsequent to their growth arrest and involved the activation of multiple immune checkpoints together with the silencing of the antigen presentation machinery.

[Clinical Cancer Research] Neuregulin-1 (NRG1) was expressed in HER2-positive breast cancer-derived fibroblasts at significantly higher levels than in cancer cells. NRG1 and the conditioned media from cancer-associated fibroblasts phosphorylated HER3 and AKT in cancer cells and mediated trastuzumab resistance.